Hims & Hers Health, Inc. is a consumer-first health and wellness platform that leverages technology to provide accessible and affordable healthcare solutions. The company offers a wide range of prescription and non-prescription products, telehealth services, and wellness content through its websites, mobile applications, and retail partnerships. Its offerings focus on addressing common health conditions, promoting lifelong wellness, and simplifying the healthcare experience for customers.
-
Online Revenue - Provides prescription and non-prescription products directly to individual customers through the company's websites and mobile applications. Includes telehealth consultations with licensed healthcare professionals who can prescribe medications when appropriate, fulfilled via licensed pharmacies.
- Prescription Products - Addresses conditions such as sexual health, hair loss, dermatology, mental health, weight loss, and primary care.
- Non-Prescription Products - Includes over-the-counter drugs, cosmetics, supplements, and wellness items such as melatonin, biotin, skincare products, sexual health products, and hair care solutions.
-
Wholesale Revenue - Sells products to wholesale partners and third-party platforms, making Hims & Hers products available in tens of thousands of retail locations across the United States.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Andrew Dudum ExecutiveBoard | CEO and Chairman | None | Co-founder of Hims, Inc. in 2016; serial entrepreneur and investor; previously co-founded Atomic Labs and other startups. Holds a B.A. in Management and Economics from Wharton. | View Report → |
Dr. Patrick Carroll Executive | Chief Medical Officer | Board Member at ChristianaCare | Rejoined Hims & Hers in December 2022; previously served as CMO for Vida Health and WHOOP. Former CMO of Walgreens. Holds a medical degree from Dartmouth Medical School. | |
Melissa Baird Executive | COO | None | Joined Hims & Hers in February 2018; previously held leadership roles at Draper James, Bonobos, and Zulily. Holds a B.S. in Biological Sciences from the University of Missouri. | |
Mike Chi Executive | Chief Commercial Officer | None | Joined Hims & Hers in April 2021; previously held leadership roles at Zola, INTERMIX, and Gilt Groupe. Brings over 20 years of experience in consumer internet. | |
Soleil Boughton Executive | Chief Legal Officer | Board Member at CaringBridge | Joined Hims & Hers in October 2018; previously in-house counsel at Google Cloud Healthcare and a partner at Jones Day. Holds a B.A. from Pomona College and a J.D. from UCLA. | |
Yemi Okupe Executive | CFO | None | Joined Hims & Hers in January 2022; previously held senior financial roles at Uber, Hipcamp, and PayPal. Holds an MBA from Stanford and is a CFA and CPA. | |
Andrea Perez Board | Director | Advisory roles for startups in services and technology sectors | Former SVP at Sony Interactive Entertainment and VP/GM at Nike. Co-founder of Women of Nike employee group. Holds a B.A. in Economics from Harvard. | |
Anja Manuel Board | Director | Board Member at Ripple Labs; Member of U.S. Defense Department Policy Board | Co-founder of Rice, Hadley, Gates & Manuel LLC; Executive Director of Aspen Strategy Group. Extensive experience in foreign policy and governance. | |
Christiane Pendarvis Board | Director | Co-CEO of PATTERN Beauty; Board Member at Hootsuite | Former Co-President of Savage X Fenty; extensive experience in DTC and retail operations. Holds a B.A. from Harvard and an MBA from UNC Kenan-Flagler. | |
Christopher Payne Board | Director | Board Member at Gogo Inc. | Former President and COO of DoorDash; previously held leadership roles at Tinder, eBay, Microsoft, and Amazon. Holds a B.S. in Commerce and English from the University of Virginia. | |
David Wells Board | Lead Independent Director | Board Member at The Trade Desk and Wise PLC | Former CFO of Netflix (2010-2019); extensive experience in financial planning and analysis. Holds a B.S. from the University of Virginia and an MBA from the University of Chicago. | |
Deb Autor Board | Director | None | Former FDA official; serves on Hims & Hers Risk Committee. Also provides consulting services to Hims & Hers. Holds extensive regulatory and compliance expertise. | |
Dr. Delos Cosgrove Board | Director | Board Member at American Well Corp. (Amwell) and View, Inc. | Former CEO of Cleveland Clinic (2004-2017); currently an Executive Advisor at Cleveland Clinic. Holds a medical degree and extensive experience in healthcare leadership. | |
Kåre Schultz Board | Director | None | Former CEO of Teva Pharmaceuticals; extensive experience in pharmaceutical and healthcare industries. Appointed to Hims & Hers board in July 2024. |
- Given the recent gross margin degradation driven by the scaling of your weight loss specialty, particularly GLP-1 offerings, how do you plan to offset these margin pressures going forward, and what are your expectations for gross margins as this segment continues to grow?
- With the evolving regulatory landscape around compounded GLP-1 medications and potential shortages of name-brand options, how do you anticipate these factors impacting your weight loss specialty, and what steps are you taking to mitigate associated risks?
- You mentioned significant investments in both 503(a) and 503(b) facilities to support personalized weight loss solutions; can you elaborate on how these investments align with your capital allocation priorities and their expected impact on operational efficiency?
- Considering that higher-priced weight loss solutions contribute to the increased average revenue per subscriber, how sustainable is this growth, and what strategies are you implementing to ensure long-term retention and diversification across other specialties?
- As you broaden your personalized and multi-specialty offerings, what challenges do you foresee in maintaining high retention rates and customer satisfaction, especially with the integration of new treatments like GLP-1s, and how do you plan to address them?
Research analysts who have asked questions during Hims & Hers Health earnings calls.
Daniel Grosslight
Citigroup
4 questions for HIMS
Eric Percher
Nephron Research
4 questions for HIMS
Maria Ripps
Morgan Stanley
4 questions for HIMS
Ryan MacDonald
Needham & Company
4 questions for HIMS
Aaron Kessler
Seaport Research Partners
3 questions for HIMS
Craig Hettenbach
Morgan Stanley
3 questions for HIMS
Jonna Kim
TD Cowen
3 questions for HIMS
David Larsen
BTIG
2 questions for HIMS
George Hill
Deutsche Bank
2 questions for HIMS
Allen Lutz
Bank of America
1 question for HIMS
Brian Tanquilut
Jefferies
1 question for HIMS
Jailendra Singh
Truist Securities
1 question for HIMS
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MedisourceRx (Seaview Enterprises LLC) | 2024 | The acquisition closed on September 5, 2024 for a total purchase price of $31.0 million structured as $15.5 million in cash and 976,341 shares of Class A common stock, and it enhanced Hims & Hers’ capabilities by acquiring a 503B compounding outsourcing facility with key allocations including $28.6 million for the pharmacy license and $1.8 million in goodwill, with post-closing adjustments within 90 days. |
Honest Health Limited (HHL) | 2021 | Acquired in June 2021 for $4.8 million (including earn-out components settled partly in 2024 via cash and stock-based compensation), the deal was aimed at broadening Hims & Hers’ presence in the UK through strategic health and wellness products, with ongoing stock compensation and earn-out adjustments finalized in 2024. |
YoDerm, Inc. (Apostrophe) | 2021 | Completed in July 2021 for a total purchase price of $131.6 million—a blend of $48.2 million in cash, 8,074,935 shares of Class A common stock, and contingent earn-out—this acquisition expanded Hims & Hers’ dermatology and personalized healthcare offerings by integrating Apostrophe’s compounding pharmacy operations and recognizing $2.7 million in goodwill. |
Recent press releases and 8-K filings for HIMS.
- Hims & Hers Health (HIMS) is facing legal risks and a stock price decline following the termination of its partnership with pharmaceutical giant Novo Nordisk, which cited allegations of illegal mass compounding and deceptive marketing practices involving GLP-1 medications.
- Truist Financial has lowered its price target for HIMS from $48 to $37 and maintained a hold rating, reflecting concerns over the company's revenue mix and growth prospects.
- In contrast, rival GoodRx Holdings secured a new partnership with Novo Nordisk to sell GLP-1 drugs, causing its shares to surge over 37%, while HIMS' trading volume recently declined by 79%.
- Despite these challenges, intra-quarter Truist Card Data indicates Hims & Hers’ GLP-1-related revenues may increase in Q3 and modestly in Q4 due to the realization of deferred revenues.
- Hims & Hers is expanding its technology-driven healthcare platform, focusing on personalization through increased CapEx investments in areas like lab diagnostics and leveraging AI for treatment optimization.
- The company plans to launch new offerings in low testosterone and menopausal support, identifying these as large and underserved markets with significant growth potential.
- In the weight loss segment, Hims & Hers is seeing strong trends in oral weight loss solutions due to broader eligibility and attractive pricing, while commercially available GLP-1s are no longer offered on the platform.
- International expansion is a key focus, with the recent acquisition of Zava for European markets and a planned launch in Canada next year coinciding with the anticipated availability of generic semaglutide.
- Core business growth is driven by oral weight loss, men's and women's dermatology, and sexual health daily business, all growing north of 55% in the most recent quarter. The sexual health on-demand business is expected to be a short-term drag but is anticipated to accelerate in 18-24 months as the company focuses on daily solutions and combined treatments.
- The Portnoy Law Firm is advising investors of Hims & Hers Health, Inc. (HIMS) regarding a class action lawsuit.
- The lawsuit's Class Period is from April 29, 2025, to June 23, 2025, with investors having until August 25, 2025, to file a lead plaintiff motion.
- Allegations state that Hims & Hers engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy®, leading to Novo Nordisk terminating its collaboration on June 23, 2025.
- Following this announcement, shares of Hims & Hers fell more than 34%.
- A class action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who purchased securities between April 29, 2025 and June 23, 2025.
- The lawsuit alleges that Hims & Hers engaged in deceptive promotion and sale of illegitimate versions of Wegovy®, leading to Novo Nordisk terminating its collaboration with the company on June 23, 2025.
- Following the announcement of the partnership termination, shares of Hims & Hers fell more than 34%.
- Investors have until August 25, 2025 to file a lead plaintiff motion in the class action lawsuit.
- Hims & Hers Health reported a mixed quarter with Q2 EPS beating expectations at $0.17 per share against an expected $0.15, but Q2 revenue missed estimates.
- Revenue for Q2 slipped quarter over quarter for both GLP-1 and core segments, and Q3 EBITDA guidance came in soft.
- The company reaffirmed its full-year outlook and its CEO reiterated a bold 2030 revenue target of $6.5 billion, despite near-term execution concerns.
- Management plans to reinvest in growth initiatives, including talent acquisition in tech and increased Q3 marketing for weight loss and other specialty products, while also noting regulatory risks related to compounded weight loss drugs.
- The stock experienced a bounce back from session lows, partly attributed to its 33% short interest.
- Hims & Hers Health reported strong Q2 2025 revenue of $545 million, a 73% year-over-year increase, and adjusted EBITDA of $82 million, while growing its subscriber base to over 2,400,000.
- The company issued an updated full-year 2025 revenue outlook of $2.3 billion to $2.4 billion and adjusted EBITDA of $295 million to $335 million.
- Strategic initiatives include the acquisition of Zava in July to expand internationally, a planned 2026 entry into Canada focusing on weight loss, and the launch of new specialties like hormonal health and lab testing.
- Hims & Hers reiterated its 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
- Hims & Hers Health, Inc. (HIMS) shares experienced a significant fall on July 25, 2025, following reports of U.S. lawmakers urging FDA action against copycat weight loss drugs and the termination of its collaboration with Novo Nordisk.
- Novo Nordisk ended its collaboration with HIMS on June 23, 2025, less than two months after it began, citing concerns about HIMS's sales and "deceptive" marketing of Wegovy®, including accusations of "illegal compounding" and mass sale of compounded versions of branded drugs.
- Securities class action lawsuits have been filed against HIMS and its executives, alleging misleading assurances to investors regarding regulatory compliance and GLP-1 drug offerings, with a Class Period from April 29, 2025, to June 23, 2025, and a Lead Plaintiff Deadline of August 25, 2025.
- Hims & Hers announced new data showing its personalized weight loss program, including compounded GLP-1s, resulted in customers losing an average of 20.9 pounds or 10.3% of initial body weight within six months.
- The program demonstrated strong adherence, with 75% of customers remaining on treatment plans over six months, significantly outperforming commercial GLP-1s which have an approximate 80% dropout rate in the same timeframe.
- The data also indicated a low incidence of side effects, with only 10.3% of customers reporting side effects and 4.5% reporting them as intolerable.
- The platform provides efficient care, offering 24/7 care team access and an average wait time of approximately 3 hours for medical intake evaluation by a licensed provider.
- Securities class action lawsuits have been filed against Hims & Hers Health, Inc. and certain executives, representing investors who purchased securities between April 29, 2025, and June 23, 2025. The lead plaintiff deadline is August 25, 2025.
- The lawsuits follow Novo Nordisk's termination of its collaboration with Hims & Hers on June 23, 2025, citing concerns over "deceptive" marketing and "illegal compounding" of Wegovy®.
- Plaintiffs allege that Hims & Hers issued misleading assurances to investors regarding its regulatory compliance and the robustness of revenue from its GLP-1 drug offerings.
- Following Novo Nordisk's announcement, Hims & Hers shares crashed 30%.
- Earlier, on February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved, which constrained Hims & Hers' ability to continue selling compounded semaglutide.
- A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) on behalf of investors who purchased securities between April 29, 2025, and June 23, 2025.
- The lawsuit alleges that Hims engaged in "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy," leading to the termination of its collaboration with Novo Nordisk on June 23, 2025.
- Following the news of the partnership termination, HIMS's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.
- Investors who suffered losses on HIMS investments are urged to contact Glancy Prongay & Murray LLP, with a lead plaintiff motion deadline of August 25, 2025.